Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (191-200 of 353) with videos related to

Pageof 36
Sort By:
American Heart Journal|July 12, 2011
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialJeffrey S Berger, Deepak L Bhatt, P Gabriel Steg, et al.
American Heart Journal|November 4, 2004
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationaleGregg W Stone, Michel Bertrand, Antonio Colombo, et al.
The American Journal of Cardiology|March 4, 2008
Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whitesGian M Novaro, Craig R Asher, Deepak L Bhatt, et al.
Diabetes Care|December 7, 2019
The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATENishant P Shah, Qiuqing Wang, Katherine E Wolski, et al.
JAMA Cardiology|December 10, 2025
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate ReductionPaul M Ridker, Florian M M Baeres, Anders Hveplund, et al.
Diabetes & Vascular Disease Research|April 25, 2019
Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trialAnirudh Kumar, Divyang R Patel, Kathy E Wolski, et al.
The American Journal of Cardiology|September 16, 2020
Implementation of a Comprehensive ST-Elevation Myocardial Infarction Protocol Improves Mortality Among Patients With ST-Elevation Myocardial Infarction and Cardiogenic ShockAnirudh Kumar, Chetan P Huded, Leon Zhou, et al.
Journal of the American College of Cardiology|September 1, 2024
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by SexSubodh Verma, Helen M Colhoun, Dror Dicker, et al.
Diabetes, Obesity & Metabolism|August 31, 2019
Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trialJeroen V Koomen, Hiddo J L Heerspink, Ilse C Schrieks, et al.
JAMA Cardiology|July 9, 2020
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE TrialRishi Puri, Steven E Nissen, Benoit J Arsenault, et al.
Pageof 36

Showing results (191-200 of 353) with videos related to

Sort By:
Pageof 36
American Heart Journal|July 12, 2011
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialJeffrey S Berger, Deepak L Bhatt, P Gabriel Steg, et al.
American Heart Journal|November 4, 2004
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationaleGregg W Stone, Michel Bertrand, Antonio Colombo, et al.
The American Journal of Cardiology|March 4, 2008
Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whitesGian M Novaro, Craig R Asher, Deepak L Bhatt, et al.
Diabetes Care|December 7, 2019
The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATENishant P Shah, Qiuqing Wang, Katherine E Wolski, et al.
JAMA Cardiology|December 10, 2025
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate ReductionPaul M Ridker, Florian M M Baeres, Anders Hveplund, et al.
Diabetes & Vascular Disease Research|April 25, 2019
Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trialAnirudh Kumar, Divyang R Patel, Kathy E Wolski, et al.
The American Journal of Cardiology|September 16, 2020
Implementation of a Comprehensive ST-Elevation Myocardial Infarction Protocol Improves Mortality Among Patients With ST-Elevation Myocardial Infarction and Cardiogenic ShockAnirudh Kumar, Chetan P Huded, Leon Zhou, et al.
Journal of the American College of Cardiology|September 1, 2024
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by SexSubodh Verma, Helen M Colhoun, Dror Dicker, et al.
Diabetes, Obesity & Metabolism|August 31, 2019
Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trialJeroen V Koomen, Hiddo J L Heerspink, Ilse C Schrieks, et al.
JAMA Cardiology|July 9, 2020
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE TrialRishi Puri, Steven E Nissen, Benoit J Arsenault, et al.
Pageof 36